Key Projects Entering the Clinical R&D Stage (As of 27 March 2025)

君实生物 TopAlliance

Phase I/II		Phase III	Approval for marketing
JS213 PD-1×IL2	**JS207** PD-1×VEGF	**Tifcemalimab** BTLA	**Toripalimab** PD-1
JS212 EGFR×HER3 ADC	**JS015** DKK1	**JS001sc** PD-1	**Adalimumab** TNF-α
JS006 TIGIT	**JS107** Claudin18.2 ADC	**JS005** IL-17A	**Deuremidevir Hydrobromide Tablets** RdRp
JS007 CTLA-4	**JS203** CD3×CD20		**Ongericimab** PCSK9
JS009 CD112R	**JS105** PI3K-α		
JS112 Aurora A	**JS110** XPO1		
JS214 VEGF×TGF-β	**JS111** EGFR exon 20		
JS010 CGRP	**JS125** HDACs		
UBP1213sc BLyS	**JT002** small nucleic acid immunomodulator		
……			

- Oncology
- Metabolism
- Immunology
- Neurologic
- Infectious disease